Clinical Trials Logo

Filter by:
NCT ID: NCT05813951 Recruiting - Treatment Efficacy Clinical Trials

Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU

NCT ID: NCT05813496 Recruiting - Clinical trials for Polyneuropathy, Diabetic

Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt

MIRACLE-ALA
Start date: October 26, 2022
Phase: Phase 4
Study type: Interventional

The purpose of the study is to find out whether ALA is effective and safe for treating Egyptian diabetic patients with symptomatic polyneuropathy. The ADA stated that despite the exploration of several pharmacological therapies for DPN management, substantial evidence on medicines that modify the natural history of DPN is still absent. This is a multicenter, interventional, two-arm, parallel-group, randomized, double-blinded, placebo-controlled, phase IV trial. Patients will be administered either one tablet of placebo or one tablet containing 600 mg of ALA twice a day for 24 weeks, depending on the randomization process.

NCT ID: NCT05813340 Recruiting - Clinical trials for Horizontal Ridge Deficiency

Vascularized Inter-positional Periosteal Connective-tissue Flap Versus Collagen Membrane in Guided Bone Regeneration

VIP-CT
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

this study compares 2 techniques in guided bone regeneration for horizontal ridge augmentation in aesthetic zone

NCT ID: NCT05813145 Recruiting - Breast Cancer Clinical Trials

Fenofibrate Role in Breast Cancer Patients

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The aim of the study is to assess the efficacy of fenofibrate in either reversing and/or preventing the development of PIPN in breast cancer patients treated with paclitaxel-based regimen. The primary outcome :clinical improvement of neuropathic pain and grade by 1-CT-CTCAE -VERSION-4 & FACT/GOG-NT-12 questionnaire and its effect on quality of life (QOL). The secondary outcome : the efficacy of fenofibrate in either reversing and/or preventing the development of PIPN via alteration of either Nerve growth factor (NGF) or/ and/( NFL).

NCT ID: NCT05812053 Recruiting - Clinical trials for Pulp Exposure, Dental

Comparative Evaluation of Eggshell Powder in Primary Teeth Pulpotomy

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

To assess & compare clinical & radiographic effects of Tea Tree Oil- Eggshell Powder and Biodentine as pulpotomy agents in primary teeth.

NCT ID: NCT05811546 Recruiting - Gastric Carcinoma Clinical Trials

Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Start date: May 1, 2022
Phase:
Study type: Observational

The goal of this cross-sectional study is to evaluate epigenetic modifications in gastric carcinogenesis, mainly in H. pylori gastritis vs gastric carcinoma. The main question[s] it aims to answer are: - How does H. pylori infection cause gastric cancer? - Can DNA methylation and other epigenetic changes predict and affect the development of gastric cancer? Formalin-fixed-paraffin-embedded tissue specimens will be obtained and reviewed for comparison between epigenetic changes in H. pylori gastritis and gastric adenocarcinoma.

NCT ID: NCT05811403 Recruiting - Clinical trials for Irreversible Pulpitis

Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This study evaluates the effect of two flushing agents (epigallocatechin gallate (EGCG) and sodium hypochlorite (NaOCl)) during full pulpotomy using two different calcium silicate-based materials (MTA and premixed bioceramic putty) on postoperative pain, success rate and dentin bridge thickness in mature permanent mandibular molars with irreversible pulpitis. Participants will be divided into four groups based on the flushing fluid and the pulp capping material to be used.

NCT ID: NCT05810415 Recruiting - Sepsis Clinical Trials

Use of Renin Versus Lactic Acid as Tissue Perfusion Biomarkers for Mortality Prediction in Hypotensive Critically Ill Patients

Start date: June 21, 2022
Phase:
Study type: Observational

Measurement of Whole Blood Lactate Concentrations Whole blood lactate concentrations will be measured at the time of study enrollment and at 24, 48, and 72 hours. Measurement of Plasma Renin Concentrations Serum renin concentration will be measured on blood samples drawn from arterial catheters on supine position right after inclusion. Discarded whole blood samples (waste blood samples) in EDTA tubes are prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours.

NCT ID: NCT05808946 Recruiting - Sepsis Clinical Trials

Alpha-Lipoic Acid in Patients With Sepsis

Start date: March 10, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Alpha-lipoic acid (ALA) is a powerful antioxidant that can help reduce the harmful effects of free radicals in the body. When the body is fighting sepsis, the immune response generates a lot of free radicals that can damage cells and tissues. ALA can neutralize these free radicals, reducing oxidative stress and preventing damage to cells and tissues. ALA also has anti-inflammatory properties, meaning it can reduce inflammation in the body. Inflammation is a key feature of sepsis, and it can cause damage to organs and tissues. By reducing inflammation, ALA can help prevent damage to organs and tissues, reducing the risk of sepsis complications such as organ failure. The objective of this research is to investigate the impact of ALA on individuals who have sepsis. The study will involve dividing the participants into two groups: a control group and an ALA group. The control group will receive the standard supportive care for sepsis management. Meanwhile, the ALA group will receive 1200 mg of ALA daily in addition to the standard care.

NCT ID: NCT05808439 Recruiting - Clinical trials for On Abdominal Aortic Aneurysms

Endovascular Repair of AAA

Start date: April 15, 2023
Phase:
Study type: Observational

We study differen t endovascular techniques as an alternative to surgical reconstruction to repair AAAS regarding ; success rates, 30-day mortality, endoleak events secondary intervention rates